William Blair Investment Management LLC Raises Stake in Astrazeneca Plc $AZN

Posted by on May 27th, 2026

William Blair Investment Management LLC boosted its holdings in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 43.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 47,059 shares of the company’s stock after purchasing an additional 14,247 shares during the period. William Blair Investment Management LLC’s holdings in Astrazeneca were worth $8,259,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Coldstream Capital Management Inc. grew its position in Astrazeneca by 2.0% during the 4th quarter. Coldstream Capital Management Inc. now owns 17,147 shares of the company’s stock worth $3,009,000 after purchasing an additional 331 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in Astrazeneca during the 4th quarter worth $1,400,000. Lloyd Advisory Services LLC. purchased a new position in Astrazeneca during the 4th quarter worth $35,000. Karras Company Inc. purchased a new position in Astrazeneca during the 4th quarter worth $3,974,000. Finally, Evoke Wealth LLC grew its position in Astrazeneca by 45.3% during the 4th quarter. Evoke Wealth LLC now owns 6,697 shares of the company’s stock worth $1,175,000 after purchasing an additional 2,089 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Astrazeneca Stock Up 0.0%

Shares of NYSE AZN opened at $187.10 on Wednesday. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The firm has a 50-day moving average price of $191.50 and a 200 day moving average price of $183.36. The stock has a market capitalization of $290.18 billion, a price-to-earnings ratio of 28.09, a price-to-earnings-growth ratio of 1.59 and a beta of 0.26.

Astrazeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Equities research analysts anticipate that Astrazeneca Plc will post 9.62 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Thursday, May 21st. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Barclays raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Finally, Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Read Our Latest Research Report on AZN

Astrazeneca Profile

(Free Report)

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

Read More

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).

Institutional Ownership by Quarter for Astrazeneca (NYSE:AZN)

Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.